Rocket Pharmaceuticals adopted a severance and change-in-control program on Aug. 21, 2026 for most U.S. employees.
CEO qualifying termination: 15 months base salary, benefits continuation; change-in-control window: 18 months base salary, target bonus, prorated target bonus.
Section 16 officers: 12 months base salary outside change in control; change-in-control: 12 months base salary, target bonus, prorated target bonus.
CEO Gaurav Shah employment agreement set base salary at USD 674,856; target annual incentive bonus at 60% of base salary.
General Counsel Martin Wilson base salary set at USD 547,313; target annual incentive bonus at 45% of base salary.
RCKT•
